ArticleBMC medical genomics2026
Characterizing SMN1 hybrid and deletion alleles using large-scale SNP array-based SMA carrier screening.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost spinal muscular atrophy (SMA) carrier screening assays quantify SMN1 exon 7 copy number, providing limited information about the prevalence or structure of SMN1-SMN2 hybrid alleles generated through gene conversion. As long-read sequencing (LRS) studies begin to resolve these alleles at high resolution, typically in modest cohorts, large population-scale data remain essential for defining the broader allele-frequency context in which such structural signatures occur.
methodsWe evaluated SMN1 exon 7 and exon 8 copy number in 18,015 individuals undergoing expanded carrier screening using a SNP-based array. Carriers were classified by deletion pattern, and representative cases underwent droplet digital PCR (ddPCR) to distinguish contiguous deletions from gene-conversion-derived hybrid alleles based on coordinated SMN1/SMN2 exon and intron copy number profiles.
resultsAmong 457 carriers (2.5%), exon 7-only deletions accounted for ~ 53%, while exon 7 + 8 deletions comprised ~ 47%. ddPCR showed that exon 7-only deletions predominantly represented SMN1-SMN2 hybrid alleles, whereas exon 7 + 8 deletions reflected contiguous loss of both exons. Isolated exon 8 deletions were rare (~ 0.05%) and likewise exhibited hybrid architecture. This distribution contrasts with earlier population studies reporting a predominance of exon 7 + 8 deletions and indicates that hybrid alleles constitute a substantial proportion of SMN1 deletion alleles in the general population.
conclusionsWhile hybrid resolution is not required for routine SMA carrier detection, the unexpectedly high prevalence of hybrid alleles highlights an important category of SMN1 structural variation that merits deeper investigation. These population-scale data provide a framework to guide and contextualize future LRS-based analyses aimed at resolving SMN1 gene-conversion tracts, allele structures, and potential modifier variants relevant to SMA pathogenesis and therapeutic response. Together, these findings support a more comprehensive understanding of SMN1 allele diversity as genomic technologies advance toward high-resolution characterization of the SMN locus.
trial registrationClinical trial number: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.